(Q33396918)

26 July 2017

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (English)

1 reference

multicenter clinical trial

26 July 2017

0 references

0 references

1 reference

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

author

Clemens-Martin Wendtner

1

Clemens-Martin Wendtner

1 reference

26 July 2017

23

Stephan Stilgenbauer

0 references

Peter Hillmen

2

Peter Hillmen

0 references

Francesc Bosch

Francesc Bosch

9

0 references

Alessandra Ferrajoli

17

Alessandra Ferrajoli

1 reference

26 July 2017

21

Michael Hallek

1 reference

26 July 2017

22

Nyla A Heerema

1 reference

26 July 2017

Eva Kimby

11

1 reference

ORCID Public Data File 2021

David D. Hurd

15

David D Hurd

1 reference

26 July 2017

Daruka Mahadevan

3

1 reference

26 July 2017

Andreas Bühler

4

1 reference

26 July 2017

Lutz Uharek

5

1 reference

26 July 2017

Steven Coutré

6

1 reference

26 July 2017

Olga Frankfurt

7

1 reference

26 July 2017

Adrian Bloor

8

1 reference

26 July 2017

Richard R Furman

10

1 reference

26 July 2017

John G Gribben

12

1 reference

26 July 2017

Marco Gobbi

13

1 reference

26 July 2017

Luke Dreisbach

14

1 reference

26 July 2017

Mikkael A Sekeres

16

1 reference

26 July 2017

Sheetal Shah

18

1 reference

26 July 2017

Jennie Zhang

19

1 reference

26 July 2017

Laure Moutouh-de Parseval

20

1 reference

26 July 2017

Asher A Chanan-Khan

24

1 reference

26 July 2017

15 November 2011

1 reference

26 July 2017

1 reference

26 July 2017

53

1 reference

26 July 2017

3

1 reference

26 July 2017

417-423

1 reference

Emerging therapies for patients with advanced chronic lymphocytic leukaemia.

26 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Disease-specific complications of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Tumour lysis syndrome: new therapeutic strategies and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.618232

10.3109/10428194.2011.618232

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference